联环药业：公司密切关注行业政策动态

Core Viewpoint - The company is actively responding to national procurement policies by optimizing product structure, enhancing production efficiency, and leveraging vertical integration to control costs and mitigate the impact of procurement on profits [1] Group 1: Strategic Adjustments - The company is adjusting its development strategy by increasing investment in innovative drugs and high-barrier generic drug research and development [1] - The focus is on product upgrades to overcome policy restrictions and reduce reliance on ordinary generic drugs [1] Group 2: Policy Engagement - The company will continue to strengthen policy research and interpretation to ensure its operational development aligns with policy directions [1] - It aims to enhance market recognition of innovative drugs through academic promotion and brand building [1] - The company is actively participating in the formulation of industry standards to improve its adaptability to policies [1]